High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-0.333
-68.85%
--
--
-0.265
-62.14%
--
--
-0.260
-66.67%
Estimates Revision
The market is revising No Change the revenue expectations for PolyPid Ltd. (PYPD) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 14.20%.
Revenue Estimates for FY2025
No Change
0.00%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
-12.97%
In Past 3 Month
Stock Price
Go Up
+14.20%
In Past 3 Month
3 Analyst Rating
Wall Street analysts forecast PYPD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PYPD is 11.00 USD with a low forecast of 9.00 USD and a high forecast of 13.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 3.940
Low
9.00
Averages
11.00
High
13.00
Current: 3.940
Low
9.00
Averages
11.00
High
13.00
Roth Capital
Buy
downgrade
$10 -> $9
2025-11-13
Reason
Roth Capital
Price Target
$10 -> $9
2025-11-13
downgrade
Buy
Reason
Roth Capital lowered the firm's price target on PolyPid to $9 from $10 and keeps a Buy rating on the shares following the Q3 report. The firm expects a positive pre-new drug application meeting and a potential filing submission in the first half of 2026 for PolyPid. Given that D-PLEX100 "enjoys multiple designations" from the FDA, it should get a six-month review, the analyst tells investors in a research note.
Roth Capital
Buy
maintain
$9 -> $10
2025-08-14
Reason
Roth Capital
Price Target
$9 -> $10
2025-08-14
maintain
Buy
Reason
Roth Capital raised the firm's price target on PolyPid to $10 from $9 and keeps a Buy rating on the shares after meeting with its management following the company's Q2 results. The firm expects a fairly uneventful pre-NDA meeting given solid D-PLEX100 clinical data, which Roth believes is poised to transform the treatment paradigm in SSI associated with colorectal cancer surgery, providing benefits to patients and healthcare systems, the analyst tells investors in a research note.
Craig-Hallum
Chase Knickerbocker
Buy
downgrade
$15 -> $13
2025-08-14
Reason
Craig-Hallum
Chase Knickerbocker
Price Target
$15 -> $13
2025-08-14
downgrade
Buy
Reason
Craig-Hallum analyst Chase Knickerbocker lowered the firm's price target on PolyPid to $13 from $15 and keeps a Buy rating on the shares following quarterly results. The biggest highlight of the quarter was the positive Shield 2 data and the following warrant inducement providing $27M and extending the cash runway into the second half of 2026, allowing them to pursue a partnership for U.S. rights to D-Plex100, with active discussions ongoing, the firm says. A development milestone from the Advanz partnership in the EU may also be coming up, Craig-Hallum adds.
Roth Capital
Buy
downgrade
$12 -> $9
2025-06-19
Reason
Roth Capital
Price Target
$12 -> $9
2025-06-19
downgrade
Buy
Reason
Roth Capital lowered the firm's price target on PolyPid to $9 from $12 and keeps a Buy rating on the shares. The firm is updating its model after the company has executed a new financing agreement that will infuse $27M worth of cash into its coffers, allowing PolyPid to schedule a pre-NDA, New Drug Application, meeting with the FDA in the coming months and potentially file the D-PLEX100 NDA in the first half of 2026, the analyst tells investors in a research note.
Citizens JMP
Outperform
downgrade
$16 -> $14
2025-06-18
Reason
Citizens JMP
Price Target
$16 -> $14
2025-06-18
downgrade
Outperform
Reason
Citizens JMP lowered the firm's price target on PolyPid to $14 from $16 and keeps an Outperform rating on the shares after the company announced that it anticipates gross proceeds of $26.7M from the exercise of 7.6M existing warrants that have been re-priced to a $3.50 exercise price and that it will issue another 7.6M warrants at $4.50. The firm's confidence is bolstered in the potential for D-PLEX100 to get to market following the warrant exercise, the analyst tells investors in a research note.
Roth Capital
Boobalan Pachaiyappan
Buy
downgrade
$12 -> $9
2025-06-18
Reason
Roth Capital
Boobalan Pachaiyappan
Price Target
$12 -> $9
2025-06-18
downgrade
Buy
Reason
Roth Capital analyst Boobalan Pachaiyappan lowered the firm's price target on PolyPid to $9 from $12 primarily due to a higher forecasted share count in Q1 2026, while keeping a Buy rating on the shares. The firm notes PolyPid has executed a new financing agreement that will infuse about $27M worth of cash into its coffers, allowing the company to schedule a pre-NDA meeting with the FDA in the coming months and potentially file the D-PLEX100 NDA in the first half of 2026.
See All Ratings
Valuation Metrics
The current forward P/E ratio for PolyPid Ltd (PYPD.O) is -3.55, compared to its 5-year average forward P/E of -1.97. For a more detailed relative valuation and DCF analysis to assess PolyPid Ltd 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-1.97
Current PE
-3.55
Overvalued PE
-0.57
Undervalued PE
-3.37
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
-0.84
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.37
Undervalued EV/EBITDA
-2.05
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
47.02
Current PS
0.00
Overvalued PS
244.56
Undervalued PS
-150.53
Financials
Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
PYPD News & Events
Events Timeline
(ET)
2025-12-03
08:40:00
PolyPid Receives FDA Meeting Minutes Supporting NDA for D-PLEX100
2025-11-12 (ET)
2025-11-12
07:35:25
PolyPid anticipates sufficient cash reserves extending through 2026
2025-11-12
07:34:53
PolyPid Announces Q3 Earnings Per Share of 37 Cents, Below Consensus Estimate of 52 Cents
Sign Up For More Events
Sign Up For More Events
News
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/default_image/newsfilter.png)
Preview
9.5
12-03NewsfilterPinnedPolyPid Receives FDA Support for D-PLEX100 NDA Submission
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/default_image/benzinga.png)
Preview
4.0
11-14BenzingaRoth Capital Reaffirms Buy Rating on PolyPid, Reduces Price Target to $9
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/cover_image/85ab04c67752a88afe5f5a367037e5b96381eff307f11b6cd4c7a59a15441978.png)
Preview
4.0
08-15BenzingaCisco To Rally Around 21%? Here Are 10 Top Analyst Forecasts For Thursday
Sign Up For More News
People Also Watch
FAQ
What is PolyPid Ltd (PYPD) stock price today?
What is PolyPid Ltd (PYPD)'s business?
What is the price predicton of PYPD Stock?
What is PolyPid Ltd (PYPD)'s revenue for the last quarter?
What is PolyPid Ltd (PYPD)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for PolyPid Ltd (PYPD)'s fundamentals?
How many employees does PolyPid Ltd (PYPD). have?